Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).
作者信息
Conduit Ciara, Inderjeeth Andrisha-Jade, Allen Raymond, Martin Andrew J, Parulekar Wendy, Mulroe Eibhlin, McJannett Margaret, Zielinski Robert R, Thomson Alastair, Tan Thean Hsiang, Sandhu Shahneen K, Reaume M Neil, Pook David W, North Scott A, Marx Gavin M, Joshua Anthony, Horvath Lisa, McDermott Ray, Chowdhury Simon, Chi Kim N, Zhang Alison Y, Stockler Martin R, Davis Ian D, Sweeney Christopher J
机构信息
aANZUP.
bRoyal Hobart Hospital, Hobart, TAS 7000.
出版信息
Future Oncol. 2025 Mar;21(6):627-636. doi: 10.1080/14796694.2024.2440277. Epub 2025 Jan 17.
Abstract
摘要
相似文献
1
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).恩杂鲁胺联合标准一线疗法治疗转移性激素敏感性前列腺癌：ENZAMET试验（ANZUP 1304）的通俗易懂总结
Future Oncol. 2025 Mar;21(6):627-636. doi: 10.1080/14796694.2024.2440277. Epub 2025 Jan 17.
2
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies.恩杂鲁胺用于转移性激素敏感性前列腺癌：ARCHES和ENZAMET随访研究的通俗概述
Future Oncol. 2025 Jan;21(1):15-24. doi: 10.1080/14796694.2024.2408101. Epub 2024 Oct 15.
3
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.睾酮抑制联合恩扎卢胺与睾酮抑制联合标准抗雄激素治疗转移性激素敏感性前列腺癌（ENZAMET）：一项国际、开放标签、随机、III 期临床试验。
Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3.
4
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.恩扎卢胺联合标准一线治疗转移性前列腺癌。
N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.
5
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.TALAPRO-2 研究结果的简明报告：他拉唑帕尼联合恩扎卢胺对比安慰剂联合恩扎卢胺用于晚期前列腺癌患者。
Future Oncol. 2024;20(29):2123-2135. doi: 10.1080/14796694.2024.2362108. Epub 2024 Jul 12.
6
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.转移性、激素敏感型前列腺癌的健康相关生活质量：ENZAMET（ANZUP 1304），由 ANZUP 领导的一项国际性、随机 III 期试验。
J Clin Oncol. 2022 Mar 10;40(8):837-846. doi: 10.1200/JCO.21.00941. Epub 2021 Dec 20.
7
Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis.将恩扎卢胺添加到一线治疗转移性激素敏感前列腺癌中：成本效益分析。
Front Public Health. 2021 Feb 9;9:608375. doi: 10.3389/fpubh.2021.608375. eCollection 2021.
8
Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world?通俗易懂的总结：在现实世界中，转移性去势抵抗性前列腺癌（mCRPC）患者服用阿比特龙或恩杂鲁胺后能活多久？
Future Oncol. 2025 May;21(11):1297-1306. doi: 10.1080/14796694.2025.2485752. Epub 2025 Apr 25.
9
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial.恩杂鲁胺与转移性前列腺癌患者的前列腺特异性抗原水平：ARCHES随机临床试验的二次分析
JAMA Netw Open. 2025 May 1;8(5):e258751. doi: 10.1001/jamanetworkopen.2025.8751.
10
Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.恩扎卢胺联合雄激素剥夺治疗对转移性激素敏感前列腺癌患者健康相关生活质量的影响：ARCHES 随机、安慰剂对照、III 期研究分析。
Eur Urol. 2020 Oct;78(4):603-614. doi: 10.1016/j.eururo.2020.03.019. Epub 2020 Apr 23.
引用本文的文献
1
May Patients Receiving GLP-1 Agonists Be at Lower Risk of Prostate Cancer Aggressiveness and Progression?接受胰高血糖素样肽-1（GLP-1）激动剂治疗的患者患侵袭性前列腺癌和疾病进展的风险会更低吗？
Cancers (Basel). 2025 May 6;17(9):1576. doi: 10.3390/cancers17091576.
Zotero 插件